Risk Factor Analysis for the Recurrence of Chronic Subdural Hematoma: A Review of 368 Consecutive Surgical Cases

Junhak Kim, MD, Jongun Moon, MD, Tackeun Kim, MD, Seongyeol Ahn, MD, Gyojun Hwang, MD, Jaeseung Bang, MD, O-Ki Kwon, MD, PhD, and Chang Wan Oh, MD, PhD
Department of Neurosurgery, Seoul National University Bundang Hospital, Seongnam, Korea

Objective: Chronic subdural hematoma (CSDH) is a common form of extra axial hemorrhage in the elderly. A surgical procedure such as a burr hole trephination is used for the CSDH treatment. The recurrence rate of CSDH is reported to range from 2.3 to 33%. In the current study, we focused on the determination of risk factors associated with the recurrence of CSDH.

Methods: We retrospectively reviewed 368 consecutive patients with CSDH treated by burr hole trephination. Univariate and multivariate analysis were performed to describe the relationships between clinical and radiological factors as well as the recurrence of CSDH.

Results: Totally 31 (8.4%) patients experienced a recurrence of CSDH in our study. The male group (10.2%) had a higher recurrence rate than the female group (3.1%). Also patients with malignant neoplasm history showed a high recurrence rate (17.9%). The recurrence rate of single layer CSDH (13.1%) and isodensity CSDH (11.7%) was highly significant also.

Conclusion: Sex, history of malignant neoplasm and the hematoma type on computed tomography were factors related with the recurrence of CSDH in our study. These findings may be supportive in the identification of patients at risk for a recurrence of CSDH.

KEY WORDS: Hematoma, subdural, chronic · Recurrence · Risk factors.
women with a mean age of 68.61 years (range 18 to 99 years). Recurrent CSDH was defined as an increase in the hemorrhage volume in the identical subdural space following a previous burr hole trephination. Computed tomography (CT) was used to diagnose all cases of CSDH. All patients with CSDH following another neurosurgical surgery were excluded. The patients were divided into two groups: the non-recurrent group and the recurrent group.

**Demographic information**

Patients’ medical histories were assessed and preoperative underlying diseases were recorded. Age, sex, hypertension, diabetes mellitus (DM) and hyperlipidemia, chronic renal failure, malignant neoplasm history and alcohol consumption were evaluated. Patients were considered to have hypertension if systolic blood pressure (BP) >160 mm Hg or diastolic BP >95 mm Hg or if patients used antihypertensive drug. Person who used DM drugs or has initial blood sugar level >200 was considered as DM patients. Hyperlipidemia was defined as abnormally elevated levels of any or all lipids or lipoprotein in the blood. Person who used anti hyperlipidemia drugs was included. Excessive chronic alcohol consumption was defined as 3 days/week for 6 months. Malignant neoplasm history was considered if the patients have a history of malignant neoplasm before diagnosis of CSDH.

Also preoperative laboratory findings and the use of antiplatelet as well as anticoagulation drugs were collected from the medical chart. Furthermore, we reviewed the presence of head trauma history, initial symptoms, time interval between the 1st operation and the 2nd operation and the surgical procedures.

**Radiological examination**

Characteristics of a hematoma were mainly assessed by CT (Figure 1). It was categorized as a single, double or as multiple layers according to the layers degree. A single layer hematoma was defined as one layer covering over brain cortex. A double layers hematoma was defined as two layers covering over brain cortex. A multiple layers hematoma was defined as above 3 layers covering the brain cortex. Additionally, characteristics of the hematoma were categorized as isodensity, hypodensity and mixed density according to the hematoma density. The hyperdensity hematoma

**FIGURE 1.** Computed tomography characteristics of chronic subdural hematoma. A: Single layer. B: Double layer. C: Multiple layer. D: Low density. E: Iso density. F: Mixed density.
was excluded from this study, because it is an acute subdural hematoma. The degree of the midline shift, the hematoma thickness and hematoma site were measured also. The midline shift was measured as the distance from the septum pellucidum point between the anterior horns of the lateral ventricles to a perpendicular line connecting the anterior and posterior insertions of the falx cerebri. The hematoma thickness was defined as the maximal thickness of the hematoma on the upper part level of the lateral ventricle. The hematoma site was measured also. Those radiological measurements were evaluated by a single investigator.

Surgical management and postoperative management

A standard surgical procedure was performed for all CSDH patients. The CSDH was removed by burr hole trephination under local anesthesia. After a dural incision, the outer membrane of the CSDH was opened and a silicon catheter was inserted into the hematoma cavity. Irrigation with isotonic saline solution was done in some patients by a silicon catheter. An external continuous drainage system was maintained for 2 to 3 days. We recommend the patients to lock the closed system drainage during walking or moving to prevent a possible over-drainage. The drainage tube was removed after the CT scan.

Statistical analysis

SPSS software (version 19.0, SPSS Inc., Chicago, IL, USA) was used for data analysis. We identified variables associated with the recurrence of CSDH with univariate and multivariate statistical analysis. Independent sample t-test and chi-squared test (or Fisher exact test) were used for univariate statistical analysis. In addition, a logistic regression model was used for multivariate statistical analysis. The relation of risk factors to CSDH recurrence was expressed as a 95% confidence interval and an odds ratio. Statistical significance was considered if the p-value was <0.05.

Results

Demographics and clinical presentation

We reviewed 368 patients with CSDH: 272 males (73.9%) and 96 females (26.1%) with a mean age of 68.6 (±13.12) years. Table 1 shows demographics and the clinical presentation of CSDH patients. The total CSDH recurrence rate was 8.4% (31 out of 368). The male group showed a 10.2% (28 out of 272) recurrence rate, while the female group showed a 3.1% (3 out of 96) recurrence rate. The difference was statistically significant (p=0.032) (Table 1).

Only 169 patients (45.9%) had a history of trauma; 158 (46.9%) patients in the non-recurrent group and 11 (35.5%) patients in the recurrent group (p=0.233). However, 199 patients (54.1%) did not have an obvious trauma history.

Headache was the most common presentation in our CSDH patients; 61.5% (207 out of 337) in the non-recurrent group and 64.5% (20 out of 31) in the recurrent group. Other symptoms contained motor weakness, dysarthria and seizure, nausea and vomiting and mental change. The presentations were not significant different between the recurrent and the non-recurrent group.

Underlying disease

Hypertension, DM and hyperlipidemia, chronic renal failure, malignant neoplasm history and alcohol consumption were analyzed by a single investigator. Preoperative laboratory findings and the use of anticoagulation drugs were also analyzed. Table 2 shows the underlying diseases and the laboratory data of the CSDH patients. All variables were not significant in the CSDH re-

| TABLE 1. Characteristics and clinical presentations in patients with chronic subdural hematoma |
|---------------------------------|-----------------|-----------------|-----------------|
| Characteristics                | Non-recurrent group (n=337) | Recurrent group (n=31) | p value |
| Age                            | 68.57 ± 13.21     | 69.00 ± 12.43    | 0.863          |
| Sex                            |                  |                  | 0.032*         |
| Female                         | 93 (27.5%)        | 3 (9.6%)         |                |
| Male                           | 244 (72.5%)       | 28 (90.4%)       |                |
| Symptoms                       |                  |                  |                |
| Headache                       | 207 (61.5%)       | 20 (64.6%)       | 0.735          |
| Motor weakness                 | 176 (52.3%)       | 17 (54.9%)       | 0.780          |
| Dysarthria                     | 74 (22.0%)        | 5 (16.1%)        | 0.449          |
| Seizure                        | 4 (1.2%)          | 0 (0%)           | 1.000          |
| Mental change                  | 29 (86.7%)        | 1 (3.2%)         | 0.494          |
| Nausea/vomiting                | 36 (10.6%)        | 4 (13.0%)        | 0.761          |

Statistical method: t-test. *statistically significant

http://www.kjnt.org
Risk Factor Analysis for the Recurrence of CSDH

...cence except of a malignant neoplasm history. Interestingly, total 28 patients (28 out of 368) demonstrated a history of malignant neoplasm; 5 patients in the recurrent CSDH group and 23 patients in the non-recurrent CSDH group. No significant difference was seen in the univariate analysis (p=0.074). However, it was significantly different in multivariate logistic analysis (p=0.025) (Table 3). Various malignant neoplasm history in CSDH patients are described in Figure 2.

**TABLE 2.** Risk factors associated to the recurrence of chronic subdural hematoma

| Factors                              | Non recurrent group (n=337) | Recurrent group (n=31) | p value |
|--------------------------------------|-----------------------------|------------------------|---------|
| Underlying disease                   |                             |                        |         |
| Hypertension                         | 190 (56.3%)/147 (43.7%)     | 14 (45.1%)/17 (54.8%)  | 0.229   |
| Diabetes mellitus                    | 275 (81.6%)/62 (18.4%)      | 25 (80.6%)/6 (19.3%)   | 0.895   |
| Hyperlipidemia                       | 313 (92.8%)/24 (7.2%)       | 30 (90.9%)/1 (9.1%)    | 0.709   |
| Anticoagulation agent use             | 327 (97.0%)/10 (3.0%)       | 31 (100%)/0 (0%)       | 1.000   |
| Antplatelet agent use                | 282 (83.6%)/55 (16.4%)      | 28 (90.3%)/3 (9.7%)    | 0.444   |
| Alcoholic                            | 288 (85.5%)/49 (14.5%)      | 27 (87.0%)/4 (13.0%)   | 1.000   |
| Malignant neoplasm history           | 314 (93.1%)/23 (6.9%)       | 26 (83.9%)/5 (16.1%)   | 0.074   |
| Chronic renal failure                | 334 (99.1%)/3 (0.9%)        | 31 (100%)/0 (0%)       | 1.000   |
| Pre-op. laboratory data              |                             |                        |         |
| Hemoglobin (g/dL)                    | 13.57 ± 1.70                | 14.04 ± 1.51           | 0.681   |
| Platelet (× 10^9/µL)                 | 235.92 ± 74.54              | 229.65 ± 71.07         | 0.141   |
| WBC (× 10^3/µL)                      | 7.86 ± 4.22                 | 6.99 ± 1.52            | 0.653   |
| INR                                  | 1.06 ± 0.31                 | 1.01 ± 0.07            | 0.384   |
| CT features                          |                             |                        |         |
| Hematoma type I                      |                             |                        | 0.028*  |
| Single layer                         | 182 (54.0%)                 | 25 (80.6%)             |         |
| Double layer                         | 76 (22.5%)                  | 4 (13.0%)              |         |
| Multiple layer                       | 79 (23.5%)                  | 2 (6.4%)               |         |
| Hematoma type II                     |                             |                        | 0.009*  |
| Isodensity                           | 152 (45.1%)                 | 20 (64.5%)             |         |
| Hypodensity                          | 81 (24.0%)                  | 10 (32.2%)             |         |
| Mixed density                        | 104 (30.9%)                 | 1 (3.3%)               |         |
| Hematoma direction                   |                             |                        | 0.944   |
| Left/right                           | 187 (55.5%)/150 (44.5%)     | 17 (54.8%)/14 (45.2%)  |         |
| Midline shift                        |                             |                        | 0.740   |
| <10 mm                               | 228 (67.6%)                 | 19 (61.2%)             |         |
| ≥ 10 mm                              | 109 (32.4%)                 | 12 (38.8%)             |         |
| Uni- or bilateral hematoma           |                             |                        | 0.066   |
| Unilateral/bilateral                 | 283 (83.9%)/54 (16.1%)      | 22 (70.9%)/9 (29.1%)   |         |
| Surgical procedures                  |                             |                        |         |
| Irrigation during operation          |                             |                        | 0.598   |
| No/yes                               | 63 (90%)/274 (91.9%)        | 7 (10%)/24 (8.1%)      |         |
| Burr hole numbers                    |                             |                        | 0.093   |
| One/two                              | 198 (83%)/139 (95.0%)       | 23 (17%)/8 (5%)        |         |

Statistical method: chi-squared test. *statistically significant, op.: operation, WBC: white blood cell, INR: international normalized ratio, CT: computed tomography
CT and CSDH recurrence rate

CT findings are summarized in Table 2. In the univariate analysis was the recurrence of CSDH not significantly associated with preoperative midline shift ($p=0.740$), hematoma site ($p=0.944$) and maximal width ($p=0.18$) of CSDH. However, the recurrence rate of CSDH was significantly related with the preoperative hematoma type. Hematoma layers significantly affected the recurrence of CSDH based on the CT. A single layer hematoma showed a CSDH recurrence rate of 80.6% (25 out of 31) whereas a double layer showed 13.0% (4 out of 31) and a multiple layer 1.1% (2 out of 31) ($p=0.028$). The hematoma density was also significantly related to the recurrence of CSDH. The isodensity recurrence of CSDH showed was 64.5% (20 out of 31) whereas the hypodensity recurrence of CSDH showed 32.2% (10 out of 31) and the mixed density recurrence rate of CSDH was 3.3% (1 out of 31) ($p=0.028$).

Hematoma characteristics are listed schematically in Figure 3. Isodensity (64.5%) and single layer (80%) rates in recurrent group was higher (45.1% and 54.0%) than those rates in non-recurrent group. Multivariate logistic analysis also shows hematoma types were also meaningful in recurrence rates (Table 3).

### TABLE 3. Risk factors associated to the recurrence of chronic subdural hematoma

| Factors                      | $p$-value | OR      | 95% CI          |
|------------------------------|-----------|---------|-----------------|
| Sex (M)                      | 0.036*    | 3.819   | 1.092–13.358    |
| Malignant neoplasm history   | 0.025*    | 3.737   | 1.178–11.853    |
| Irrigation during operation  | 0.976     | 0.976   | 0.379–2.565     |
| Uni- or bilateral hematoma   | 0.139     | 1.921   | 0.808–4.569     |
| Hematoma type I              | 0.023*    | 0.086   | 0.119–1.149     |
| Double layer                 |           | 0.370   |                 |
| Multiple layer               | 0.018*    | 0.158   | 0.034–0.733     |
| Hematoma type II             | 0.049     |         |                 |
| Hypodensity                  | 0.822     | 0.907   | 0.388–2.119     |
| Mixed density                | 0.014*    | 0.077   | 0.010–0.597     |

Statistical method: logistic regression analysis. *statistically significant, reference: single layer, reference: isodensity. OR: odds ratio, 95% CI: 95% confidence interval.
Risk Factor Analysis for the Recurrence of CSDH

ized in Table 2. The number of burr holes was not related to the recurrence of CSDH in univariate analysis ($p=0.093$) and in logistic multivariate analysis ($p=0.066$). Irrigation was also not significantly meaningful to the recurrence of CSDH in univariate analysis ($p=0.598$) and in logistic multivariate analysis ($p=0.97$). Our average recurrence interval was 38.26 ($\pm 4.05$) days. Also a 2nd operation was performed through previous a burr hole site or a new burr hole site.

Outcomes

Almost all of our patients had great postoperative outcomes. Although 4 patients (4 of 368) needed a 2nd burr hole trephination, the overall outcome of 364 patients (364 of 368) was good. Only 4 patients needed an additional craniotomy and hematoma removal, because CSDH developed an acute subdural hematoma after the burr hole trephination.

Discussion

Many researchers reported risk factors related to the recurrence of CSDH including age, alcohol abuse, bilateral CSDH, hematoma density and technical surgical procedures. However, risk factors were generally inconsistent. Therefore, we assessed the risk factors associated with the recurrence of CSDH through univariate and multivariate analysis. Thereby, we came to the conclusion that sex, malignant neoplasm history and the hematoma type on the CT scan were related to the recurrence of CSDH.

Demographics and clinical presentation

Generally, an occurrence of CSDH in older people comes from an age-related decrease in brain volume, increase of the tension on the cerebral bridging vein and an increased venous fragility associated with aging. This tendency might be different in the male and the female group. The male gender was definitely related to the recurrence of CSDH with a significant difference between both groups ($p=0.032$) (Table 1). Generally, male are predisposed to develop CSDH. Our study also showed trauma history of the male was much than those of the female consistently. In fact, the male group had a much higher chance to suffer from a trauma to the head than the female group. There is a theoretic possibility that higher levels of estrogen in the female group may have some protective effect on capillaries. In addition, estrogen is related to the repair of damaged vessels, because estrogen is known to induce vascular repair and angiogenesis.

Many studies revealed an apparent head trauma history up to 74.4% of CSDH. However, our data showed a definite trauma history in only 169 patients (45.9%) (169 out of 368). If a minor trauma is so trivial, people tend to forget their trauma history. Furthermore, indirect trauma is also reported as important factor. Although 50% of the patients had a history of fall, patients did not hit their head on the ground. Even if it is not absolutely proportional to the occurrence of CSDH, the head trauma history is very important in CSDH.

Underlying disease

Interestingly was the malignant neoplasm history statistically significant in our study. It was insignificant in univariate analysis ($p=0.074$), but significant in multivariate analysis ($p=0.025$). Patients with a malignant neoplasm history showed a higher CSDH recurrence rate (16.1%) (5 out of 31) than other patients (6.9%) (23 out of 337).

The frequency of intracerebral hemorrhage in malignant neoplasm has been reported different and varied depending on the underlying malignancy. Risk factors for intracerebral hemorrhage include neovascularization, vascular invasion and coagulation imbalance. Also, many case reports showed a relationship between brain metastasis of malignant neoplasm and CSDH. Authors suggested a multifactorial pathogenesis of CSDH in malignancy such as dural vessel occlusion and rupture by tumor cells, tumor necrosis and chemotherapy-induced thrombocytopenia or disseminated intravascular coagulation secondary to an underlying malignancy. Authors suggested that CSDH seems easily to occur in patients with malignant neoplasm. However, our study could not show a definite metastatic brain tumor in any CSDH patient. Because our sample size was small, it is not correct that previous malignant neoplasm can affect recurrence of CSDH exactly. Further research is additionally needed to look for a relationship between CSDH recurrence and a malignant neoplasm history.

CT and CSDH recurrence rate

A CT is well known as a useful tool for the diagnosis of CSDH. Therefore, we mainly used CT to evaluate CSDH. Our data showed single layer hematoma was significant in the recurrence of CSDH. Single layer hematoma showed 80.6% (25 out of 31) recurrence rates of CSDH.

The recurrence rate of CSDH showing isodensity was 64.5% (20 out of 31) ($p=0.009$). These findings correspond well to one result reported in the literature. Therefore, the isodensity of CSDH might also be important as a radiological factor of CSDH recurrence. However, Mori and Maeda and Tsai et al. could not detect a positive correlation between radiological images based on CT density and re-
currence. Saito et al. also did not detect a positive association between radiological images and CSDH recurrence. He concluded that chemical factors of the hematoma membrane may show a better relationship with the CSDH recurrence than radiological characteristics. His study showed only for chemical factors such as vascular endothelial growth factor and transforming growth factor-β influence on the vascularization of the hematoma membrane. Further studies are consistently required as the relationship between radiological factors and CSDH recurrence remains still unclear.

Surgical procedures and the recurrence of CSDH

We mostly performed burr hole trephination through parietal eminence. The number of burr holes in each operation showed no specific differences in our study (p=0.093). Other studies showed no significant differences in the recurrence rate between 1 hole and 2 holes trephination also. However, Taussky et al. found a significantly higher rate of recurrence for 1 hole trephination. Their data showed a longer length of hospital stay and an increased rate of wound infection in the group with 1 hole trephination.

Conclusion

Some factors have been shown as relatively significant. In our study we sex, history of a malignant neoplasm and the type of hematoma (single and isodensity) factors related to the recurrence of CSDH. Therefore, CSDH patients with risk factors should be followed closely, even if there is no trauma history present.

The authors have no financial conflicts of interest.

REFERENCES

1) Abdulhamid MM, Li YM, Hall WA. Spontaneous acute subdural hematoma as the initial manifestation of chronic myeloid leukemia. J Neurooncol 101:513-516, 2011
2) Abouzari M, Rashidi A, Rezaei J, Esfandiari K, Askari M, Aleali H, et al. The role of postoperative patient posture in the recurrence of traumatic chronic subdural hematoma after burr-hole surgery. Neurosurgery 61:794-797; discussion 797, 2007
3) Adhiyanman V, Asghar M, Ganeshram KN, Bhownick BK. Chronic subdural haematoma in the elderly. Postgrad Med J 78:71-75, 2002
4) Barnabas O, Wang H, Gao XM. Role of estrogen in angiogenesis in cardiovascular diseases. J Geriatr Cardiol 10:377-382, 2013
5) Han HJ, Park CW, Kim EY, Yoo CJ, Kim YB, Kim WK. One vs. Two Burr Hole Craniostomy in Surgical Treatment of Chronic Subdural Hematoma. J Korean Neurosurg Soc 46:87-92, 2009
6) Huang YH, Yang KY, Lee TC, Liao CC. Bilateral chronic subdural hematoma: what is the clinical significance? Int J Surg 11:544-548, 2013
7) Kanssi R, Nadkarni T, Goel A. Single versus double burr hole drainage of chronic subdural hematomas. A study of 267 cases. J Clin Neurosci 17:428-429, 2010
8) Kimura S, Kotani A, Takimoto T, Yoshino A, Katayama Y. Acute aggravation of subdural fluid collection associated with dural metastasis of malignant neoplasms: case report and review of the literature. Brain Tumor Pathol 31:299-303, 2014
9) Kostanian V, Choi JC, Liker MA, Go JL, Zee CS. Computed tomographic characteristics of chronic subdural hematomas. Neurosurg Clin N Am 11:479-480, 2000
10) Kuan-Yin T, Dueng-Yuan H, Hsin-I M. Subdural hematoma associated with skull and dural metastasis of gastric carcinoma: a case report. Turk Neurosurg 23:796-799, 2013
11) Laigle-Donadey F, Talilbert S, Mokhtari K, Hildebrand J, Delattre JY. Dural metastases. J Neurooncol 75:57-61, 2005
12) Liwnicz BH, Wu SZ, Tew JM Jr. The relationship between the capillary structure and hemorrhage in gliomas. J Neurosurg 66:536-541, 1987
13) Mori K, Maeda M. Surgical treatment of chronic subdural hematoma in 500 consecutive cases: clinical characteristics, surgical outcome, complications, and recurrence rate. Neurol Med Chir (Tokyo) 41:371-381, 2001
14) Nagatani K, Takeuchi S, Sakakibara F, Otani N, Nawashiro H. Radiological factors related to recurrence of chronic subdural hematoma. Acta Neurochir (Wien) 153:1713, 2011
15) Navi BB, Reichman JS, Berlin D, Reiner AS, Panagkas GS, Segal AZ, et al. Intracerebral and subarachnoid hemorrhage in patients with cancer. Neurology 74:494-501, 2010
16) Prasad BC, Chandra VV, Varapradasg D. Dural metastases in chronic myeloid leukemia presenting as subdural hematoma. Turk Neurosurg 22:777-778, 2012
17) Rogers LR. Cerebrovascular complications in cancer patients. Neurol Clin 21:167-192, 2003
18) Rozzelle CJ, Wofford JL, Branch CL. Predictors of hospital mortality in older patients with subdural hematoma. J Am Geriatr Soc 43:240-244, 1995
19) Saito A, Narisawa A, Takasawa H, Morita T, Sannehe S, Sasaki T, et al. Expression of the TGF-β—ALK-1 pathway in dura and the outer membrane of chronic subdural hematomas. Neurol Med Chir (Tokyo) 54:357-362, 2014
20) Schrader B, Barth H, Lang EW, Buhl R, Hugo HH, Biederer J, et al. Spontaneous intracranial haematomas caused by neoplasms. Acta Neurochir (Wien) 142:979-985, 2000
21) Spallone A, Giuffré R, Gagliardi FM, Vagnozzi R. Chronic subdural hematoma in extremely aged patients. Eur Neurol 29:18-22, 1989
22) Stanisic M, Hald J, Rasmussen IA, Pripp AH, Ivanovic J, Kolstad F, et al. Volume and densities of chronic subdural haematoma obtained from CT imaging as predictors of postoperative recurrence: a prospective study of 107 operated patients. Acta Neurochir (Wien) 155:323-333; discussion 333, 2013
23) Taussky P, Pandino J, Landick H. Number of burr holes as independent predictor of postoperative recurrence in chronic subdural haematoma. Br J Neurosurg 22:279-282, 2008
24) Torihashi K, Sadiama N, Yoshida K, Narumi O, Chin M, Yamagata S. Independent predictors for recurrence of chronic subdural hematoma: a review of 343 consecutive surgical cases. Neurosurgery 63:1125-1129; discussion 1129, 2008
25) Tsai TH, Liu AS, Hwang SL, Huang TY, Hwang YF. A comparative study of the patients with bilateral or unilateral chronic subdural hematoma: precipitating factors and postoperative outcomes. J Trauma 68:571-575, 2010
26) Weigel R, Schmiedek P, Krauss JK. Outcome of contemporary surgery for chronic subdural haematoma: evidence based review. J Neurol Neurosurg Psychiatry 74:937-943, 2003
27) Yamamoto H, Hiroshima Y, Hamada H, Hayashi N, Origasa H, Endo S. Independent predictors of recurrence of chronic subdural hematoma: results of multivariate analysis performed using a logistic regression model. J Neurosurg 98:1217-1221, 2003